Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DeLuca, R. V.
Right arrow Articles by Almenoff, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DeLuca, R. V.
Right arrow Articles by Almenoff, P. L.
(Chest. 1999;115:1533-1538.)
© 1999 American College of Chest Physicians

Effects of a ß2-Agonist on Airway Hyperreactivity in Subjects With Cervical Spinal Cord Injury*

Richard V. DeLuca , MD; David R. Grimm , EdD; Marvin Lesser , MD; William A. Bauman , MD and Peter L. Almenoff , MD, FCCP

* From the Spinal Cord Damage Research Center, Veterans Affairs Medical Center, Bronx, NY, and The Mount Sinai School of Medicine, Mount Sinai Medical Center, New York.

Study objective: Aerosolized ipratropium bromide or orally administered baclofen or oxybutynin chloride (Ditropan) block methacholine-associated airway hyperreactivity in subjects with chronic cervical spinal cord injury (SCI), whereas these agents do not inhibit airway hyperreactivity associated with the inhalation of histamine. The present study was performed to determine whether pretreatment with a ß2-agonist attenuates airway hyperresponsiveness in these subjects.

Participants: Subjects with chronic cervical SCI previously demonstrating airway hyperreactivity were challenged with methacholine (n = 9) or histamine (n = 16) alone and, on a separate day, 25 min following inhalation of nebulized metaproterenol sulfate.

Results: Inhalation of the ß2-agonist was associated with an increase in provocative concentration causing a 20% decrease in FEV1 (PC20) values (geometric mean) from 1.01 ± 2.76 to 20.54 ± 6.24 mg/mL for methacholine and from 2.29 ± 2.26 to 19.82 ± 5.93 mg/mL for histamine. No correlation was found between specific PC20 values for individual subjects and percentage improvement in FEV1 (liter) following inhalation of metaproterenol sulfate and between PC20 values and baseline FEV1 percent.

Conclusion: These data, combined with findings that patients with chronic high cervical SCI experience increased breathlessness following exposure to exogenous agents, suggest that long-term prophylactic ß2-agonist therapy may reduce respiratory symptoms associated with airway hyperreactivity in these patients.

Key Words: ß2-agonist • bronchial hyperresponsiveness • histamine • methacholine • quadriplegia • spinal cord injury




This article has been cited by other articles:


Home page
 ChestHome page
G. J. Schilero, D. R. Grimm, W. A. Bauman, R. Lenner, and M. Lesser
Assessment of Airway Caliber and Bronchodilator Responsiveness in Subjects With Spinal Cord Injury
Chest, January 1, 2005; 127(1): 149 - 155.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. R. Grimm, D. Chandy, P. L. Almenoff, G. Schilero, and M. Lesser
Airway Hyperreactivity in Subjects With Tetraplegia Is Associated With Reduced Baseline Airway Caliber
Chest, November 1, 2000; 118(5): 1397 - 1404.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.